Corona Remedies Ltd
Q1 FY27, unaudited
- Revenue
- ₹422.43 Cr
- Profit after tax
- ₹60.11 Cr
As filed with the exchange, consolidated basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 422.43 | — | 1,403.18 |
| Other income | 3.15 | — | 10.65 |
| Total income | 425.58 | — | 1,413.83 |
| Employee benefit expense | 122.09 | — | 403.02 |
| Finance costs | 2.69 | — | 6.97 |
| Depreciation & amortisation | 13.24 | — | 37.87 |
| Total expenses | 345.23 | — | 1,154.58 |
| Profit before tax | 80.35 | — | 240.42 |
| Tax expense | 20.25 | — | 55.30 |
| Profit after tax | 60.11 | — | 185.12 |
| Total comprehensive income | 59.81 | — | 185.23 |
| Earnings per share, basic | ₹9.83 | ₹30.27 |
|---|---|---|
| Earnings per share, diluted | ₹9.83 | ₹30.27 |
Q1 FY27 — unaudited, from the company’s filing with NSE. Source
FY26 — from the company’s filing with NSE. Source
Q1 FY27 results for every company Parakho holds
Why the dash
Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.
Earnings call
Q1 FY27CORONA Remedies reported Q1 FY27 revenue growth of 21.9% year-on-year to Rs 422 crores, with EBITDA growing 33.5% and PAT growing 30.1%. Management said the India business grew 22.7%, outperforming the Indian Pharmaceutical Market's 11.6% growth, driven by a mix of volume, pricing and new product launches. The company also commercialized a new EU-GMP approved hormone manufacturing facility during the quarter and reaffirmed its FY27 revenue and profit growth targets.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.
Earlier calls: Q4 FY26 · All quarters
Filings
12 shown · 61 published by the exchange
05 Oct 2026
30 Sept 2026
Credit rating28 Sept 2026
Insider trading19 Sept 2026
Insider tradingDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Appears 2 times in the recent filings shown; listed once.
18 Sept 2026
10 Sept 2026
10 Sept 2026
FilingClarification sought from Corona Remedies Ltd
20 Aug 2026
10 Aug 2026
Transcript10 Aug 2026
03 Aug 2026
01 Aug 2026
Filing
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Industry
Healthcare › Pharmaceuticals
Classification as published by BSE.
Companies also in Pharmaceuticals, in alphabetical order
Page generated from filings held to 05 Oct 2026.